Ionis Pharmaceuticals Inc (IONS) - Total Liabilities
Based on the latest financial reports, Ionis Pharmaceuticals Inc (IONS) has total liabilities worth $2.42 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Ionis Pharmaceuticals Inc growing its equity to track the company's year-over-year net asset growth rate.
Ionis Pharmaceuticals Inc - Total Liabilities Trend (1990–2024)
This chart illustrates how Ionis Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See IONS free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Ionis Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Ionis Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Verona Pharma plc
F:I9SA
|
Germany | €294.60 Million |
|
360 Security Technology Inc
SHG:601360
|
China | CN¥8.41 Billion |
|
Brenntag SE
F:BNR
|
Germany | €6.28 Billion |
|
Huolinhe Opencut Coal Industry Corp Ltd of Inner Mongolia
SHE:002128
|
China | CN¥14.21 Billion |
|
Meridian Energy Ltd
AU:MEZ
|
Australia | AU$6.24 Billion |
|
Autoliv Inc
ST:ALIV-SDB
|
Sweden | Skr5.86 Billion |
|
Sartorius Aktiengesellschaft
XETRA:SRT3
|
Germany | €5.98 Billion |
|
Zhejiang China Commodities City Group Co Ltd
SHG:600415
|
China | CN¥20.18 Billion |
Liability Composition Analysis (1990–2024)
This chart breaks down Ionis Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IONS stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ionis Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ionis Pharmaceuticals Inc (1990–2024)
The table below shows the annual total liabilities of Ionis Pharmaceuticals Inc from 1990 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.42 Billion | -7.22% |
| 2023-12-31 | $2.60 Billion | +32.76% |
| 2022-12-31 | $1.96 Billion | +6.58% |
| 2021-12-31 | $1.84 Billion | +18.94% |
| 2020-12-31 | $1.55 Billion | -0.06% |
| 2019-12-31 | $1.55 Billion | +4.55% |
| 2018-12-31 | $1.48 Billion | +63.91% |
| 2017-12-31 | $903.30 Million | +11.12% |
| 2016-12-31 | $812.90 Million | +7.62% |
| 2015-12-31 | $755.32 Million | +8.21% |
| 2014-12-31 | $698.03 Million | +48.91% |
| 2013-12-31 | $468.77 Million | +29.17% |
| 2012-12-31 | $362.92 Million | +15.78% |
| 2011-12-31 | $313.46 Million | +2.46% |
| 2010-12-31 | $305.94 Million | -13.85% |
| 2009-12-31 | $355.12 Million | -24.43% |
| 2008-12-31 | $469.90 Million | +89.01% |
| 2007-12-31 | $248.62 Million | +57.35% |
| 2006-12-31 | $158.00 Million | -3.48% |
| 2005-12-31 | $163.71 Million | -41.65% |
| 2004-12-31 | $280.56 Million | +4.78% |
| 2003-12-31 | $267.76 Million | -5.45% |
| 2002-12-31 | $283.21 Million | +46.01% |
| 2001-12-31 | $193.96 Million | +65.94% |
| 2000-12-31 | $116.89 Million | +14.25% |
| 1999-12-31 | $102.31 Million | +2.00% |
| 1998-12-31 | $100.30 Million | +20.84% |
| 1997-12-31 | $83.00 Million | +93.47% |
| 1996-12-31 | $42.90 Million | +81.01% |
| 1995-12-31 | $23.70 Million | +15.05% |
| 1994-12-31 | $20.60 Million | +1.48% |
| 1993-12-31 | $20.30 Million | +29.30% |
| 1992-12-31 | $15.70 Million | +8.28% |
| 1991-12-31 | $14.50 Million | +457.69% |
| 1990-12-31 | $2.60 Million | -- |
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pe… Read more